BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24879340)

  • 21. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
    Sung CO; Song IH; Sohn I
    Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
    Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
    Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
    Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Who are the long-term survivors of high grade serous ovarian cancer?
    Hoppenot C; Eckert MA; Tienda SM; Lengyel E
    Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
    Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
    BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
    Spentzos D; Levine DA; Ramoni MF; Joseph M; Gu X; Boyd J; Libermann TA; Cannistra SA
    J Clin Oncol; 2004 Dec; 22(23):4700-10. PubMed ID: 15505275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.
    Shawky Ael-A; El-Hafez AA; El-Tantawy D; Hamdy R
    Asian Pac J Cancer Prev; 2014; 15(10):4275-9. PubMed ID: 24935384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
    Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
    Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
    BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
    Candido-dos-Reis FJ; Song H; Goode EL; Cunningham JM; Fridley BL; Larson MC; Alsop K; Dicks E; Harrington P; Ramus SJ; de Fazio A; Mitchell G; Fereday S; Bolton KL; Gourley C; Michie C; Karlan B; Lester J; Walsh C; Cass I; Olsson H; Gore M; Benitez JJ; Garcia MJ; Andrulis I; Mulligan AM; Glendon G; Blanco I; Lazaro C; Whittemore AS; McGuire V; Sieh W; Montagna M; Alducci E; Sadetzki S; Chetrit A; Kwong A; Kjaer SK; Jensen A; Høgdall E; Neuhausen S; Nussbaum R; Daly M; Greene MH; Mai PL; Loud JT; Moysich K; Toland AE; Lambrechts D; Ellis S; Frost D; Brenton JD; Tischkowitz M; Easton DF; Antoniou A; Chenevix-Trench G; Gayther SA; Bowtell D; Pharoah PD; ; ;
    Clin Cancer Res; 2015 Feb; 21(3):652-7. PubMed ID: 25398451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
    Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
    Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting DNA repair: the genome as a potential biomarker.
    Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
    J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
    J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.